Related Experiment Video

Updated: May 16, 2026

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening

Published on: October 26, 2017

MicroRNAs as potential biomarkers in human solid tumors

Jun Shen1, Sanford A Stass, Feng Jiang

  • 1Department of Pathology, University of Maryland School of Medicine, 10 South Pine Street, Baltimore, MD 21201, USA.

Cancer Letters
|December 1, 2012
PubMed

Insights

MicroRNAs (miRNAs) are crucial for cell function and cancer development. Analyzing circulating miRNAs in body fluids offers promising potential for diagnosing and predicting solid tumors, despite existing challenges.

Area of Science:

  • Molecular Biology
  • Genetics
  • Oncology

Background:

  • MicroRNAs (miRNAs) regulate a significant portion of human gene expression.
  • Aberrant miRNA expression is implicated in the development and progression of various human solid tumors.
  • Extracellular miRNAs circulating in body fluids are emerging as potential biomarkers.

Purpose of the Study:

  • To review the current advancements in analyzing microRNAs for solid cancer diagnosis and prognosis.
  • To discuss the challenges associated with developing circulating miRNAs as reliable biomarkers.

Main Methods:

  • Literature review of studies analyzing microRNA expression in solid cancers.
  • Analysis of extracellular microRNAs in body fluids for diagnostic and prognostic applications.
  • Discussion of technical and biological hurdles in biomarker development.

Main Results:

  • MicroRNAs play critical roles in cellular homeostasis and malignancy.
  • Abnormal miRNA profiles are characteristic of many solid tumors.
  • Circulating miRNAs show potential for non-invasive cancer detection and outcome prediction.

Conclusions:

  • MicroRNA analysis represents a promising avenue for cancer diagnostics and prognostics.
  • Overcoming obstacles in standardization and validation is key to clinical translation of miRNA biomarkers.
  • Further research is needed to fully harness the potential of circulating miRNAs in oncology.

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...